Get the Stockscreener App
285.04
1.07%
3.03
Krystal Biotech Inc stock is traded at $285.04, with a volume of 264.60K.
It is up +1.07% in the last 24 hours and up +19.49% over the past month.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
See More
Previous Close:
$282.01
Open:
$284.17
24h Volume:
264.60K
Relative Volume:
0.89
Market Cap:
$8.27B
Revenue:
$290.51M
Net Income/Loss:
$89.16M
P/E Ratio:
95.33
EPS:
2.99
Net Cash Flow:
$119.18M
1W Performance:
+9.04%
1M Performance:
+19.49%
6M Performance:
+89.93%
1Y Performance:
+96.84%
1-Day Range:
$282.00
$289.78
1-Week Range:
$257.00
$295.98
52-Week Range:
$122.80
$295.98
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
285.04 | 8.18B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Krystal Biotech gets expanded FDA approval for Vyjuvek - MSN
Krystal Biotech: Beyond VYJUVEK Commercialization (NASDAQ:KRYS) - Seeking Alpha
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Update and CORAL-3 Plans - Sahm
Activity Recap: Will Krystal Biotech Inc outperform small cap indexes2025 Institutional Moves & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Krystal Biotech (KRYS) Price Target Increased by 18.96% to 269.93 - Nasdaq
Krystal Biotech (BIT:1KRYS) Price Target Increased by 19.80% to 226.45 - Nasdaq
Movement Recap: What is Krystal Biotech Inc.’s market position2025 Short Interest & Daily Profit Maximizing Tips - baoquankhu1.vn
KRYS Stock: Citigroup Raises Price Target to $336, Maintains Buy - GuruFocus
KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives - sharewise.com
Citigroup Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price - MarketBeat
Avoiding Lag: Real-Time Signals in (KRYS) Movement - Stock Traders Daily
Krystal Biotech stock maintains Buy rating at H.C. Wainwright on strong revenue - Investing.com Canada
Krystal Biotech outlines rare disease growth strategy update - TipRanks
Krystal Biotech, Inc. (KRYS) Stock Analysis: Navigating A Promising 4.05% Potential Upside - DirectorsTalk Interviews
Credo Technology Group Holding And 2 Insider Picks For Strong Growth - Yahoo Finance
Krystal Biotech Reports ~$389M 2025 VYJUVEK Revenue, $955M Cash Reserves - Nasdaq
Krystal Biotech expects Vyjuvek net revenue of $106 million to $107 million for Q4 2025 - marketscreener.com
Rpt-Krystal Biotech Expects VYJUVEK Net Revenue Of $106 Million To $107 Million For Q4 2025 - TradingView — Track All Markets
Krystal Biotech Announces Preliminary 4Q 2025 VYJUVEK Revenue of $106-$107 Million and Strategic Vision for Growth in Rare Disease Market - Quiver Quantitative
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Krystal Biotech expects net revenue of $106 million to $107 million for Q4 2025 - marketscreener.com
Krystal Biotech Expects Net Revenue Of $106 Million To $107 Million For Q4 2025 - TradingView — Track All Markets
Inside one company's plan to reach 10,000 rare disease patients - Stock Titan
Krystal Biotech rises on new phase 1 data for cystic fibrosis asset - MSN
Krystal Biotech Reports $107M VYJUVEK Revenue for Q4 2025 - Intellectia AI
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Data And FDA Study Filing - Yahoo Finance
Is Krystal Biotech (KRYS) Still Attractively Priced After Its Strong Multi Year Share Price Run - Yahoo Finance
Krystal Biotech (NASDAQ:KRYS) Reaches New 1-Year High Following Analyst Upgrade - MarketBeat
KRYS: TD Cowen Raises Price Target and Maintains Buy Rating | KR - GuruFocus
Assessing Krystal Biotech (KRYS) Valuation After Positive KB407 Cystic Fibrosis Trial Update - Yahoo Finance
Recent price trend in Krystal Biotech (KRYS) is your friend, here's why - MSN
Krystal Biotech (KRYS) Rises on Positive Phase 1 Data for Cystic Fibrosis Treatment - GuruFocus
Krystal Biotech (NASDAQ:KRYS) Stock Price Up 7%Still a Buy? - MarketBeat
Krystal Biotech stock price target raised to $306 by TD Cowen on CF data - Investing.com Canada
Krystal Biotech stock hits all-time high at 265.99 USD By Investing.com - Investing.com Canada
Citigroup Raises Price Target for Krystal Biotech (KRYS) to $320 - GuruFocus
Krystal Biotech stock hits all-time high at 265.99 USD - Investing.com India
Krystal Biotech stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Nigeria
Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why - Yahoo Finance
Krystal Biotech stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
Krystal Biotech stock price target raised to $288 from $272 at BofA - Investing.com Canada
Aug Momentum: Will Krystal Biotech Inc. stock reach all time highs in 2025 - Улправда
KRYS: HC Wainwright & Co. Raises Price Target to $310 | KRYS Sto - GuruFocus
Krystal Biotech (NASDAQ:KRYS) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
Jefferies raises Krystal Biotech stock price target to $310 on CF data By Investing.com - Investing.com South Africa
Jefferies raises Krystal Biotech stock price target to $310 on CF data - Investing.com Australia
Assessing Krystal Biotech (KRYS) Valuation As Investors Await CORAL-1 KB407 Interim Cystic Fibrosis Data - Sahm
Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path - Yahoo Finance
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):